- •CONTENTS
- •Contributors
- •Preface
- •I Components of Angiogenic Cascades
- •1. Introduction and Historical Perspective
- •2. The Semaphorins
- •3. The Plexin Receptor Family
- •4. The Neuropilins
- •5. Vascular Endothelial Growth Factors and Their Receptors
- •6. Signal Transduction by Neuropilins
- •7. The Role of the Neuropilins in the Regulation of Vasculogenesis and Angiogenesis
- •8. Modulation of Angiogenesis by Semaphorins that Bind Directly to Plexins
- •Acknowledgments
- •References
- •1. Introduction
- •1.1. Eph receptor domain structure
- •1.2. The ephrin domain structure
- •2. Effects on Vascular Cell Behavior and Signaling Pathways
- •2.1. Ephrin-A1 and EphA2
- •2.2. Ephrin-A1 and EphA4
- •2.3. Ephrin-B and EphB
- •2.3.1. EphB forward signaling
- •2.3.2. Ephrin-B reverse signaling
- •2.4. Crosstalk with other angiogenic pathways
- •3. Endothelial Cell Fate
- •4. Angiogenic Remodeling of Embryonic Blood Vessels
- •4.1. Ephrin-A1 and EphA receptors
- •4.2. EphB4 and Ephrin-B2
- •4.3. Other EphB receptors and Ephrin-Bs
- •5. Lymphatic Vessels
- •6. Adult Vasculature
- •6.1. Quiescent vasculature
- •6.2. Physiological angiogenesis
- •6.3. Inflammation and wound healing
- •6.4. Tumor angiogenesis
- •6.4.1. Ephrin-A1 and EphA2
- •6.4.2. Ephrin-B2 and EphB4
- •8. Perspectives
- •Acknowledgments
- •References
- •1. Introduction
- •2. Molecular Mechanisms
- •3. Role in Vascular Development
- •4. FGFs in Tumor Angiogenesis
- •5. Role of FGFs in Developmental and Tumor Lymphangiogenesis
- •7. Conclusion
- •Acknowledgments
- •References
- •1. The NPY System
- •2. NPY as a Growth Factor for Vascular Cells
- •3. DPPIV: A Molecular Switch of the NPY Angiogenic System
- •4. Downstream Mediators of NPY Actions
- •5. NPY in Revascularization of Ischemic Tissues
- •6. NPY in Wound Healing
- •7. NPY in Adipose Tissue Growth and Obesity
- •8. NPY in Retinopathy
- •10. NPY in Tumor Angiogenesis
- •11. NPY-Mediated Angiogenesis and Neurogenesis
- •References
- •1. Introduction
- •2. Historical Perspective
- •3.1. The HSPG core proteins
- •3.2. The structure of the HS chain
- •3.3. The biosynthesis of HS
- •3.4. The post-synthetic processing of HSPGs
- •4. Evolution of HSPGs
- •5. HSPGs in Development
- •6. HSPG Modulation of Ligand-Receptor Interactions
- •6.2. HSPG co-receptors confer unique regulatory properties
- •6.2.1. Co-receptors engender stoichiometric control of signaling
- •6.2.2. The effects of glycanation
- •6.2.3. HS sequence motifs regulate signaling
- •7. HSPGs Enable Global Control of EC Phenotype
- •8. Future Therapeutic Directions
- •9. Conclusions
- •References
- •II Angiogenic Regulators
- •1. Introduction: Blood Vessels and Nerves Use Similar Guidance Cues
- •2. Semaphorin Signaling
- •2.1. Neuropilins
- •2.2. Plexins
- •3. Ephrins and Eph Signaling
- •3.1. Forward signaling
- •3.2. Reverse signaling
- •4. Netrin and Slit Signaling
- •5. Open Questions
- •References
- •1. Oxygen Homeostasis: Phylogeny, Ontogeny, Physiology, and Pathobiology
- •5. Control of Angiogenesis and Arteriogenesis by HIF-1
- •6. Control of Tumor Angiogenesis by HIF-1
- •References
- •1. Introduction
- •2. Reactive Oxygen Species (ROS) in the Vasculature
- •3. ROS and Angiogenesis
- •4. NAD(P)H Oxidase: A Major Source of ROS in the Vasculature
- •5. Role of NAD(P)H Oxidase in Angiogenesis
- •6. ROS as Signaling Molecules in Angiogenesis
- •8. Conclusion
- •References
- •1. Introduction
- •2. Assessing Coronary Angiogenesis and Arteriogenesis
- •3. Pressure Overload-Induced Hypertrophy
- •4. Volume Overload-Induced Cardiac Hypertrophy
- •5. Thyroxine-Induced Hypertrophy
- •6. Hypoxia-Induced Hypertrophy
- •7. Exercise-Induced Hypertrophy
- •8. Myocardial Infarction-Induced Hypertrophy
- •9. Modulators of Angiogenesis During Hypertrophy
- •10. Stimuli of Angiogenesis During Hypertrophy
- •11. Summary
- •References
- •1. Introduction
- •2. Coronary Resistance
- •3. Regulation of Coronary Microvascular Tone
- •3.1. Intrinsic and extrinsic vasomotor control
- •3.2. Role of the endothelium
- •3.3. Role of metabolism and autoregulation
- •3.4. Flow-induced dilation
- •3.5. Neurohumoral influence on microcirculation
- •3.6. Intrinsic myogenic tone
- •3.7. Impact of extravascular and humoral factors on the coronary microcirculation
- •3.8. Role of venules in coronary resistance
- •4. Endothelial Factors in Vascular Growth and Response to Injury
- •5. Impact of Disease States on Coronary Circulation
- •6. The Coronary Microcirculation in Hypertophic States
- •7. Summary
- •References
- •III Clinical Applications
- •1. Kinase Inhibition and Tumor Angiogenesis
- •2. Major Angiogenesis Factors and Receptors
- •2.1. VEGF signaling
- •3. Further Angiogenesis-Related Signaling
- •4. Need for Selectivity of Anti-Angiogenic Kinase Inhibitors
- •5. Kinase Inhibitors in Clinical Development
- •5.1. BAY 43-9006 (Sorafenib)
- •5.2. PTK/ZK (Vatalanib)
- •5.3. SU11248 (Sunitinib)
- •5.9. BIBF 1120
- •5.10. Chir-258
- •5.12. SU5416 (Semaxinib)
- •6. Challenges and Future Directions
- •Acknowledgments
- •References
- •1. Introduction
- •2. Concepts and Rationales
- •3. Strategy
- •4. Clinical Trials
- •4.1. Growth factor-based, angiogenic approach
- •4.2. Cell therapy-based, vasculogenic and paracrine approach
- •5. Issues Regarding Current Strategy
- •5.1. Choice of biological agent
- •5.2. Pharmacokinetics and delivery mode
- •5.3. Monitoring of neovascularization
- •5.4. Study design
- •6. Emerging Concepts of Therapeutic Angiogenesis
- •6.1. Neovascularization responsiveness
- •6.2. Genetic determination of neovascularization
- •7. Future Prospective
- •8. Summary
- •References
- •1. Hepatocyte Growth Factor in Cardiovascular System
- •2. HGF Signaling in Endothelial Cells
- •3. Angiogenic Therapy for Ischemic Peripheral Arterial Diseases
- •4. Clinical Trial in PAD
- •5. HGF Gene Therapy for Myocardial Ischemia
- •6. HGF Gene Therapy for Restenosis After Angioplasty
- •7. Next Five Years Perspective — Future Direction of HGF Therapy
- •Acknowledgments
- •References
- •1. Endothelial Nitric Oxide in Health and Disease
- •1.1. Nitric oxide synthases
- •1.2. Physiological role of endothelial NO (“EDNO”)
- •1.3. Endothelial NO-deficiency in cardiovascular diseases
- •1.4. Therapeutic restoration of endothelial NO production in cardiovascular diseases
- •2. Nitric Oxide and Angiogenesis
- •2.2. Tumor angiogenesis and NO
- •2.3. Evidence in cultured endothelial cells and in rabbit cornea
- •2.4. Role of NO in post-ischemic revascularization
- •2.6. Molecular mechanisms
- •3. NOS Gene Transfer
- •3.1. Gene delivery vectors
- •3.2. NOS-III gene transfer
- •3.3. NOS-II gene transfer
- •4.1. Impaired angiogenesis and arteriogenesis in patients with critical limb ischemia
- •4.2.1. NOS-III-KO mice
- •4.2.2. NOS-III transgenic mice
- •4.2.3. Wild-type NOS-III gene transfer in normal rats
- •4.5.1. Plasmid delivery of the NOS1177D gene
- •4.5.2. Adenoviral delivery of the NOS1179D gene
- •6. Conclusions
- •Acknowledgments
- •References
- •Index
9
Angiogenesis and
Arteriogenesis in
Cardiac Hypertrophy
by Robert J. Tomanek and Eduard I. Dedkov
1. Introduction
A continuous O2 supply is necessary for the myocardium since its anaerobic capacity is limited. Coronary flow and O2 utilization are linearly coupled and blood flow may increase four-to-five fold when myocardial work is extreme.1 Accordingly, the myocardium has a rich supply of microvessels, i.e. capillaries and arterioles. When myocytes enlarge in response to increased work, vascular density will decrease unless an appropriate stimulus for angiogenesis is triggered. A limitation or lack of capillary growth will increase diffusion distance for oxygen, while inadequate arteriolar growth will limit maximal myocardial perfusion. Since maximal flow will be decreased due to the larger heart mass, coronary reserve (the difference between maximal and resting flows) will be compromised. Thus, for cardiac hypertrophy to be effective as a compensator for increased work, adequate angiogenesis and arteriogenesis must also occur.
253
254 R. J. Tomanek & E. I. Dedkov
In some models of cardiac hypertrophy (e.g. thyroxine-induced) angiogenesis and/or arteriogenesis are well documented. In other models, vascular growth may be limited or virtually non-existent. Thus, some stimuli that evoke cardiac hypertrophy are associated with factors that promote vascular growth. Accordingly, this review examines various models of cardiac hypertrophy and possible mechanisms that underlie angiogenesis and/or arteriogenesis.
2. Assessing Coronary Angiogenesis and Arteriogenesis
Since most of vascular resistance resides in arterioles, growth of this component (arteriogenesis) will facilitate a better maximal myocardial perfusion. Growth of these vessels may occur via formation of new arterioles or by remodeling of existing arterioles to increase their diameters (Fig. 1). For optimal O2 diffusion, angiogenesis, i.e. sprouting or splitting (intussusception) of capillaries, needs to occur in order to attenuate or prevent increases in capillary domains, i.e. the tissue served by one capillary. Thus, when ventricular mass increases, regardless of the stimulus, normalization of (1) maximal myocardial perfusion and (2) capillary domains are necessary for adequate O2 delivery, especially during periods of high metabolic demand.
Maximal myocardial perfusion evaluated during pharmacologicallyinduced maximal vasodilation provides an estimate of the extent of the vascular bed. Radioactive or fluorescent microspheres are injected to estimate perfusion and values are adjusted for perfusion pressure and expressed as “conductance.” Another way of appraising the growth is to express the perfusion data as “minimal coronary vascular resistance” (pressure/flow). Morphometric approaches enable the extent of specific components of the coronary vasculature to be quantified. Numerical density (number of vessels/mm2 tissue) is a commonly used estimate. Length density (aggregate length of vessels in a volume of tissue) is a more accurate gauge of vascularity and is not affected by orientation of plane of sectioning. The same is true of volume density.
3. Pressure Overload-Induced Hypertrophy
Hypertension and aortic or pulmonary artery coarctation are the most common causes of cardiac hypertrophy encountered in the clinical
Angiogenesis and Arteriogenesis in Cardiac Hypertrophy |
255 |
Fig. 1. Vascular growth in response to cardiac hypertrophy may include: (1) angiogenesis, i.e. growth of capillaries by sprouting or intussusception (partitioning to bifurcate a capillary), and (2) arteriogenesis, i.e. creation of a new arteriole via recruitment of smooth muscle cells to an endothelial tube, or remodeling of an existing arteriole or artery to increase its diameter.
setting. In humans, long-term pressure overload-induced hypertrophy is associated with a decrease in coronary reserve, which has generally been attributed to an absence or inadequate growth of the coronary vasculature. Many experimental studies on animal models with various forms of pressure overload have also concluded that angiogenesis, if it occurs, does not compensate for the increase in ventricular mass (reviewed in Refs. 2 and 3). A decline in coronary reserve and/or maximal myocardial perfusion has also been documented in a variety of animal species, e.g. rat, cat, pig and dog.4−10 However, hypertension, as well as cardiac hypertrophy, contribute to the decline in coronary reserve.11 Work from our lab showed that cardiac hypertrophy and arterial pressure could be dissociated.12,13 Normalization of blood pressure with hydralazine in spontaneously hypertensive rats markedly reduced minimal coronary
256 R. J. Tomanek & E. I. Dedkov
vascular resistance and normalized coronary reserve, despite the persistence of cardiac hypertrophy.13 Subsequently, we explored the effect of reversing established cardiac hypertrophy and elevated blood pressure on maximal myocardial perfusion.14 ACE inhibition normalized arterial pressure and minimal coronary vascular resistance, even though it did not totally regress left ventricular hypertrophy. Thus, impairment of flow in pressure overload hypertrophy is due, in part, to the chronic hypertension-altered vessel reactivity, e.g. impaired dilation.11
Proliferation of endothelial cells in the myocardium of rats with either aortic constriction or renal hypertension was absent as shown by [3H] thymidine labeling.15. Inadequate capillary growth results in increased diffusion distances and capillary domains, i.e. the tissue served by a capillary.2,16 In contrast, several studies have shown that right or left ventricular hypertrophy in response to pressure overload can be associated with proportional vascular growth of the coronary vasculature (Table 1). In spontaneously hypertensive rats, stabilization of myocardial hypertrophy permits capillary growth to compensate for the additional cardiac mass.17,18 Moreover, coronary reserve and minimal coronary vascular resistance normalize over time.5,19 The angiogenesis associated with stabilized hypertrophy correlates with an elevation in VEGF mRNA which has been shown to occur at 28 and 32 weeks of age in SHR.20 Dogs with renal hypertension (one kidney, one clip) of six weeks duration were found to have moderate (27%) left ventricular hypertrophy and a 67% increase in minimal coronary vascular resistance.10 However, when the renal hypertension was prolonged to seven months, dogs exhibited normal LV-MCVR, arteriolar numeral densities, despite the fact that LV weight was higher than controls.21
Right ventricular hypertrophy evoked by pulmonary artery banding in dogs,22 and swine23,24 was associated with normal or decreased MCVR. Arteriogenesis, as indicated by arteriolar densities that were similar to the controls, occurred in a model of progressive pulmonary artery constriction that caused a 91% increase in RV weight.24 Capillary density, however, was lower in the pressure overload group, a finding that supports the concept that growth of capillaries and arterioles is not necessarily parallel. In sum, there are many reports in the literature that
Angiogenesis and Arteriogenesis in Cardiac Hypertrophy |
257 |
Table 1. Angiogenesis and arteriogenesis in pressure overload cardiac hypertrophy.
|
Type of |
|
|
|
overload and |
|
|
|
magnitude of |
|
|
Ref. no. |
hypertrophy |
Species |
Findings |
|
|
|
|
18 |
SHR LV |
Rat |
Capillary proliferation |
|
weight ↑ |
|
between 21 and 45 days: |
|
24%–27% |
|
normal NA, capillary/myocyte |
|
|
|
ratio increased |
22 |
P.A. band |
Young dogs |
Lower MCVR |
|
RVW ↑ 2.5× |
|
|
23 |
P.A. band |
Young swine |
Normal MCVR and |
|
RVW/BW ↑ |
|
arteriolar density |
|
112% |
|
|
24 |
Progressive |
Adult mini pigs |
Normal MCVR and |
|
P.A. |
|
arteriolar density |
|
constriction |
|
|
21 |
Renal |
Dogs |
Normal MCVR |
|
hypertension |
|
Normal arteriolar density |
|
(1K, 1C) |
|
|
|
LVW/BW ↑ |
|
|
|
46% |
|
|
19 |
SHR |
Rat |
Peak flow velocity, |
|
LVW/BW ↑ |
|
repayment/delete ratio ↓ at 3 |
|
15%, 25%, 29% |
|
and 7 months, normal at 12 |
|
|
|
months |
17 |
Spontaneous |
Rat |
Capillary density ↓ at peak |
|
hypertension |
|
hypertrophy (7 months) then |
|
|
|
normalized at 12 months |
5 |
Spontaneous |
Rat |
Coronary reserve normalized |
|
hypertension |
|
when hypertrophy stabilized |
LV = Left ventricle; RV = right ventricle; P.A. = pulmonary artery; MCVR = minimal coronary vascular resistance; 1K = one kidney; 1C = one clip; SHR = spontaneously hypertensive rat.
